Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid

AUTOR(ES)

Howe, Robin A.

FONTE

American Society for Microbiology

RESUMO

The susceptibilities of clinical vancomycin-intermediate Staphylococcus aureus (VISA), heterogenous VISA, and laboratory-generated linezolid-resistant S. aureus strains to the new oxazolidinone AZD2563 were assessed by agar dilution MIC determination. All clinical strains were susceptible to linezolid, and the linezolid MICs for them were equal to or twofold higher than those of AZD2563. Cross-resistance with linezolid was seen in laboratory-generated mutants, and for these strains the MIC of AZD2563 was twofold higher than that of linezolid.

Documentos Relacionados

• In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates
• In Vitro Activity of the New Oxazolidinone AZD2563 against Enterococci
• Comparative Activities of the Oxazolidinone AZD2563 and Linezolid against Selected Recent North American Isolates of Streptococcus pneumoniae
• In Vitro Activity of Ramoplanin against Clostridium difficile, Including Strains with Reduced Susceptibility to Vancomycin or with Resistance to Metronidazole
• Emergence in Asian Countries of Staphylococcus aureus with Reduced Susceptibility to Vancomycin